IGF-1 LR3 vs DES(1–3): Research Comparison and COA Review
Comparing IGF-1 LR3 vs DES(1–3) starts with the identity of each variant and the experimental question. The available comparative studies do not justify a universal rule that LR3 is the “long-lasting” choice and DES is the “tenfold more potent” choice.
For Research Use Only. Not for human or veterinary use.
Structural comparison
| Feature | IGF-1 LR3 | DES(1–3) IGF-I |
|---|---|---|
| Structural change | A 13-amino-acid N-terminal extension and an arginine substitution at position 3 of IGF-I. | Removal of the first three N-terminal residues of IGF-I: Gly-Pro-Glu. |
| Research comparison | Specify the exact variant, matrix, comparator and measured endpoint. | |
| Batch documentation | Review the lot-specific identity and purity results; check separately for any functional testing. | |
These structural descriptions appear in the comparative bovine immune-cell study. They identify different materials, not interchangeable names for the same reagent.
Binding-protein effects and assay context
Both variants have been studied in relation to reduced IGFBP affinity. That property is relevant to experimental interpretation, but it does not establish a single potency ratio between them. Binding affinity, receptor activation and a downstream cellular response are distinct outcomes.
In bovine immune-cell experiments, the relative responses to the variants differed between the readouts examined. In porcine granulosa-cell experiments, responses also varied with the cell subpopulation and collection conditions. Neither study supports assigning one variant a fixed advantage across all research systems.
How to evaluate a comparison
- Identify the endpoint. A binding assay and a cellular response assay answer different questions.
- Check the comparator. A difference relative to native IGF-I is not automatically a difference relative to LR3 or DES.
- Read the experimental context. Record the cell model, matrix and observation period alongside the result.
- Separate activity from duration. A culture response does not establish circulating half-life, storage stability or a human exposure profile.
- Check transferability. Treat results from a different model as background evidence, not a guaranteed outcome for another experiment.
Does LR3 last longer, and is DES more potent?
This guide does not present “20–30 hours” as a general LR3 half-life or DES as universally tenfold more potent than LR3. Such claims require a directly applicable study and a clearly defined comparison. Variant selection should follow the research question and validated methods for the model, rather than an unsupported timescale or potency ranking.
What a COA can and cannot establish
Confirm that the report identifies the correct variant and lot. Review the identity method, purity method, reported results and supporting data where available. An intact-mass result alone is not complete sequence confirmation, and chromatographic purity does not establish biological potency.
Endotoxin, sterility, residual solvents and other attributes require their own documented tests where relevant. Their absence from a report should not be interpreted as a passing result. Likewise, independent testing documents the tested sample; it does not eliminate the need to review each lot.
Related resources
For the LR3-specific discussion, see IGF-1 LR3 research: structure, evidence and COA review. Current IGF-1 LR3 specifications and the batch COA library provide separate product and documentation references. This comparison is educational and does not imply that both variants are offered in the catalog.
Primary research references
- Effects of IGF-I and its analogues on bovine immune-cell assays — structural descriptions and assay-specific comparisons.
- Insulin and IGFs stimulate IGF-binding protein production by ovarian granulosa cells — binding-protein context in a cellular model.
- Differential responses of porcine granulosa-cell subpopulations to IGF-1 analogues — dependence on cell population and experimental conditions.